JP2024522373A - Ｄｎａポリメラーゼシータ阻害剤としてのｏ結合チアジアゾリル化合物 - Google Patents
Ｄｎａポリメラーゼシータ阻害剤としてのｏ結合チアジアゾリル化合物 Download PDFInfo
- Publication number
- JP2024522373A JP2024522373A JP2023576009A JP2023576009A JP2024522373A JP 2024522373 A JP2024522373 A JP 2024522373A JP 2023576009 A JP2023576009 A JP 2023576009A JP 2023576009 A JP2023576009 A JP 2023576009A JP 2024522373 A JP2024522373 A JP 2024522373A
- Authority
- JP
- Japan
- Prior art keywords
- independently selected
- pharma
- alkyl
- acceptable salt
- ceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163209555P | 2021-06-11 | 2021-06-11 | |
| US63/209,555 | 2021-06-11 | ||
| US202263319826P | 2022-03-15 | 2022-03-15 | |
| US63/319,826 | 2022-03-15 | ||
| PCT/IB2022/055384 WO2022259204A1 (en) | 2021-06-11 | 2022-06-09 | O-linked thiadiazolyl compounds as dna polymerase theta inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024522373A true JP2024522373A (ja) | 2024-06-18 |
| JP2024522373A5 JP2024522373A5 (https=) | 2025-06-13 |
Family
ID=82358548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023576009A Pending JP2024522373A (ja) | 2021-06-11 | 2022-06-09 | Ｄｎａポリメラーゼシータ阻害剤としてのｏ結合チアジアゾリル化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240287080A1 (https=) |
| EP (1) | EP4352055A1 (https=) |
| JP (1) | JP2024522373A (https=) |
| KR (1) | KR20240044412A (https=) |
| AU (1) | AU2022289762B2 (https=) |
| BR (1) | BR112023025245A2 (https=) |
| CA (1) | CA3222078A1 (https=) |
| CL (1) | CL2023003671A1 (https=) |
| CO (1) | CO2023017082A2 (https=) |
| IL (1) | IL308912A (https=) |
| MX (1) | MX2023014665A (https=) |
| TW (1) | TW202315618A (https=) |
| WO (1) | WO2022259204A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023202623A1 (zh) * | 2022-04-20 | 2023-10-26 | 南京再明医药有限公司 | Polq抑制剂化合物及其应用 |
| AU2023352129A1 (en) * | 2022-09-29 | 2025-05-01 | Repare Therapeutics Inc. | N-(5-substituted-[(1,3,4-thiadiazolyl) or (1,3-thiazolyl)](substituted)carboxamide compounds, pharmaceutical compositions, and methods of preparing the amide compounds and of their use |
| CN117946138A (zh) * | 2022-10-28 | 2024-04-30 | 杭州圣域生物医药科技有限公司 | 并环含氮化合物、其中间体、制备方法和应用 |
| WO2024099336A1 (en) * | 2022-11-10 | 2024-05-16 | Danatlas Pharmaceuticals Co., Ltd. | Thiadiazolyl derivatives, compositions and uses thereof |
| JP2025541823A (ja) * | 2022-12-09 | 2025-12-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー４）、リミテッド | Ｄｎａポリメラーゼシータ阻害剤としてのチアジアゾリル誘導体およびその使用 |
| WO2024149349A1 (zh) * | 2023-01-14 | 2024-07-18 | 西藏海思科制药有限公司 | 靶向Polθ的化合物及其用途 |
| TW202502745A (zh) * | 2023-02-28 | 2025-01-16 | 美商賽堤爾醫療公司 | ４，５－稠和雙環吡咯啶及４，５－稠和雙環吡咯啶－酮化合物 |
| US12215102B2 (en) * | 2023-02-28 | 2025-02-04 | Reglagene, Inc. | Compositions and methods for making and using small molecules for tubulin-targeted therapy in the treatment of cancers and related conditions |
| KR20250153866A (ko) | 2023-03-10 | 2025-10-27 | 브레이크포인트 테라퓨틱스 게엠베하 | Dna 중합효소 세타 억제제 |
| WO2024211836A2 (en) | 2023-04-05 | 2024-10-10 | Moma Therapeutics, Inc. | Semi-saturated bicyclic derivatives and related uses |
| WO2024213082A1 (en) * | 2023-04-13 | 2024-10-17 | Danatlas Pharmaceuticals Co., Ltd. | Thiadiazolone derivatives, compositions and uses thereof |
| CN121712768A (zh) * | 2023-05-30 | 2026-03-20 | 宁波新湾科技发展有限公司 | 噻唑基或噻二唑基酰胺衍生物及其用途 |
| CN121399118A (zh) * | 2023-06-02 | 2026-01-23 | 成都微芯药业有限公司 | Polθ抑制剂及其制备方法和用途 |
| EP4727540A2 (en) * | 2023-06-16 | 2026-04-22 | Quantx Biosciences US, Inc. | Fused bicyclic heterocyclic or hetero aryl amide compounds |
| WO2025011617A1 (zh) * | 2023-07-12 | 2025-01-16 | 杭州圣域生物医药科技有限公司 | 并环杂芳环类化合物、其中间体、制备方法和应用 |
| WO2025016391A1 (zh) * | 2023-07-18 | 2025-01-23 | 南京再明医药有限公司 | 噻唑并吡嗪类化合物及其应用 |
| CN121773109A (zh) * | 2023-07-27 | 2026-03-31 | 北京丹擎医药科技有限公司 | PolQ降解剂及其组合物和应用 |
| WO2025036490A1 (zh) * | 2023-08-17 | 2025-02-20 | 海思科医药集团股份有限公司 | 一种DNA聚合酶θ抑制剂及其用途 |
| KR20260040065A (ko) * | 2023-09-01 | 2026-03-23 | 항저우 신알엑스 테라퓨틱스 바이오메디컬 테크놀로지 컴퍼니 리미티드 | 바이아릴 고리계 화합물, 이의 중간체, 제조 방법 및 용도 |
| CN117229260B (zh) * | 2023-11-13 | 2024-02-27 | 中国药科大学 | DNA聚合酶θ与聚ADP核糖聚合酶1双靶点抑制剂及其制备方法和医药用途 |
| WO2025110780A1 (en) * | 2023-11-24 | 2025-05-30 | Daewoong Pharmaceutical Co., Ltd. | Novel heterocyclic compounds and pharmaceutical composition comprising the same as dna polymerase theta inhibitors for the prevention or treatment of cancer |
| WO2025165092A1 (en) * | 2024-01-30 | 2025-08-07 | Daewoong Pharmaceutical Co., Ltd. | Novel heterocyclic compounds and pharmaceutical composition comprising the same as dna polymerase theta inhibitors for the prevention or treatment of cancer |
| CN120829441A (zh) * | 2024-04-24 | 2025-10-24 | 杭州圣域生物医药科技有限公司 | 一种并环含氮化合物及其中间体的制备方法 |
| CN120829442A (zh) * | 2024-04-24 | 2025-10-24 | 杭州圣域生物医药科技有限公司 | 一种并环含氮化合物及其中间体的制备方法 |
| WO2025223483A1 (zh) * | 2024-04-24 | 2025-10-30 | 杭州圣域生物医药科技有限公司 | 并环含氮化合物、其晶型及其制备方法和用途 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010513444A (ja) * | 2006-12-21 | 2010-04-30 | アストラゼネカ アクチボラグ | 新規化合物 |
| WO2011065402A1 (ja) * | 2009-11-25 | 2011-06-03 | 日本たばこ産業株式会社 | インドール化合物及びその医薬用途 |
| JP2017537948A (ja) * | 2014-12-17 | 2017-12-21 | ジャンキョテックス スイス エスアーＧｅｎｋｙｏｔｅｘ Ｓｕｉｓｓｅ Ｓａ | Ｎａｄｐｈオキシダーゼ阻害剤としてのアミドチアジアゾール誘導体 |
| WO2019079297A1 (en) * | 2017-10-16 | 2019-04-25 | Dana-Farber Cancer Institute, Inc. | COMPOUNDS AND METHODS OF TREATING CANCER |
| WO2020243459A1 (en) * | 2019-05-31 | 2020-12-03 | Ideaya Biosciences, Inc. | Thiadiazolyl derivatives as dna polymerase theta inhibitors |
| JP2023552764A (ja) * | 2020-12-02 | 2023-12-19 | イデアヤ、バイオサイエンシズ、インコーポレイテッド | Ｄｎａポリメラーゼシータ阻害剤としての置換チアジアゾリル誘導体 |
-
2022
- 2022-06-08 TW TW111121145A patent/TW202315618A/zh unknown
- 2022-06-09 EP EP22735990.8A patent/EP4352055A1/en active Pending
- 2022-06-09 JP JP2023576009A patent/JP2024522373A/ja active Pending
- 2022-06-09 AU AU2022289762A patent/AU2022289762B2/en active Active
- 2022-06-09 KR KR1020247000980A patent/KR20240044412A/ko active Pending
- 2022-06-09 CA CA3222078A patent/CA3222078A1/en active Pending
- 2022-06-09 MX MX2023014665A patent/MX2023014665A/es unknown
- 2022-06-09 WO PCT/IB2022/055384 patent/WO2022259204A1/en not_active Ceased
- 2022-06-09 IL IL308912A patent/IL308912A/en unknown
- 2022-06-09 US US18/567,687 patent/US20240287080A1/en active Pending
- 2022-06-09 BR BR112023025245A patent/BR112023025245A2/pt unknown
-
2023
- 2023-12-07 CO CONC2023/0017082A patent/CO2023017082A2/es unknown
- 2023-12-07 CL CL2023003671A patent/CL2023003671A1/es unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010513444A (ja) * | 2006-12-21 | 2010-04-30 | アストラゼネカ アクチボラグ | 新規化合物 |
| WO2011065402A1 (ja) * | 2009-11-25 | 2011-06-03 | 日本たばこ産業株式会社 | インドール化合物及びその医薬用途 |
| JP2017537948A (ja) * | 2014-12-17 | 2017-12-21 | ジャンキョテックス スイス エスアーＧｅｎｋｙｏｔｅｘ Ｓｕｉｓｓｅ Ｓａ | Ｎａｄｐｈオキシダーゼ阻害剤としてのアミドチアジアゾール誘導体 |
| WO2019079297A1 (en) * | 2017-10-16 | 2019-04-25 | Dana-Farber Cancer Institute, Inc. | COMPOUNDS AND METHODS OF TREATING CANCER |
| WO2020243459A1 (en) * | 2019-05-31 | 2020-12-03 | Ideaya Biosciences, Inc. | Thiadiazolyl derivatives as dna polymerase theta inhibitors |
| JP2023552764A (ja) * | 2020-12-02 | 2023-12-19 | イデアヤ、バイオサイエンシズ、インコーポレイテッド | Ｄｎａポリメラーゼシータ阻害剤としての置換チアジアゾリル誘導体 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3222078A1 (en) | 2022-12-15 |
| KR20240044412A (ko) | 2024-04-04 |
| AU2022289762A1 (en) | 2023-12-14 |
| US20240287080A1 (en) | 2024-08-29 |
| CL2023003671A1 (es) | 2024-07-12 |
| WO2022259204A1 (en) | 2022-12-15 |
| CO2023017082A2 (es) | 2024-04-18 |
| TW202315618A (zh) | 2023-04-16 |
| EP4352055A1 (en) | 2024-04-17 |
| IL308912A (en) | 2024-01-01 |
| BR112023025245A2 (pt) | 2024-02-20 |
| AU2022289762B2 (en) | 2025-12-04 |
| MX2023014665A (es) | 2024-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024522373A (ja) | Ｄｎａポリメラーゼシータ阻害剤としてのｏ結合チアジアゾリル化合物 | |
| JP7655863B2 (ja) | Ｄｎａポリメラーゼシータ阻害剤としてのチアジアゾリル誘導体 | |
| JP7487421B2 (ja) | Ｐｒｍｔ５阻害剤 | |
| JP7787819B2 (ja) | 新規ｐｒｍｔ５阻害剤 | |
| US11840513B2 (en) | Substituted nicotinimide inhibitors of BTK for treating cancer | |
| AU2019246753B2 (en) | Novel compounds and compositions for inhibition of FASN | |
| JP2023552764A (ja) | Ｄｎａポリメラーゼシータ阻害剤としての置換チアジアゾリル誘導体 | |
| TWI824309B (zh) | 作為PI3K-γ抑制劑之雜環化合物 | |
| KR102249236B1 (ko) | Ｐｉ３ｋ 억제제로서 헤테로시클릴아민 | |
| ES2555168T3 (es) | Compuestos de heteroaril piridona y aza-piridona como inhibidores de la actividad de Btk | |
| JP2021193099A (ja) | 置換４−アザインドール及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用 | |
| TW201326173A (zh) | ５，７－經取代之－咪唑并［１，２－ｃ］嘧啶 | |
| ES2967489T3 (es) | Imidazopirazinonas, pirazolopirimidinonas y pirazolopiridinonas como inhibidores de PDE1 | |
| JP2018521025A (ja) | Ｔｎｆ活性のモジュレーターとしてのベンゾオキサジノン誘導体およびその類似体 | |
| KR20210151833A (ko) | Eed 및 prc2 조절제로서 마크로사이클릭 아졸로피리딘 유도체 | |
| TW202440111A (zh) | 作為ｗｒｎ抑制劑之雜環化合物 | |
| KR20230104782A (ko) | Bcr-abl 티로신 키나제 억제용 7-아자인돌 화합물 | |
| JP2018536685A (ja) | ヘテロ芳香族ｎｍｄａ受容体モジュレーターおよびその使用 | |
| CN117794927A (zh) | 作为DNA聚合酶θ抑制剂的O-连接噻二唑基化合物 | |
| CN117083271A (zh) | 作为DNA聚合酶θ抑制剂的取代的噻二唑基衍生物 | |
| TW201305181A (zh) | 酞嗪酮類衍生物、其製備方法及其在醫藥上的應用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250605 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250605 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260224 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20260226 |